564
Hronová K, Šíma M, Světlík S, et al. Pharmacogenetics and immunosuppressive drugs. Expert Rev
Clin Pharmacol. 2014;7:821–35.
Huizinga TW. Personalized medicine in rheumatoid arthritis: is the glass half full or half empty.
J Int Med. 2014. doi: 10.1111/joim.12319.
Kim S, Poursine-Laurent J, Truscott SM, et al. Licensing of natural killer cells by host major his-
tocompatibility complex class I molecules. Nature. 2005;436:709–13.
Liu Y, Aryee MJ, Padyukov L, et al. Epigenome-wide association data implicate DNA methylation
as an intermediary of genetic risk in rheumatoid arthritis. Nat Biotech. 2013;31:142–7.
Paczesny S, Braun TM, Levine JE. Elafi n is a biomarker of graft-versus-host disease of the skin.
Sci Transl Med. 2010;2:13ra2.
Pieringer H, Studnicka-Benke A. What is causing my arthritis, doctor? A glimpse beyond the usual
suspects in the pathogenesis of rheumatoid arthritis. QJM. 2013;106:219–28.
Plenge RM, Seielstad M, Padyukov L, et al. TRAF1–C5 as a risk locus for rheumatoid arthritis – a
genomewide study. N Engl J Med. 2007;357:1199–209.
Sarwal MM. Deconvoluting the ’omics for organ transplantation. Curr Opin Organ Transplant.
2009;14:544–51.
Taniguchi A, Urano W, Tanaka E, Kamatani N. Pharmacogenomics of antirheumatic drugs and
personalized medicine for rheumatoid arthritis. Nippon Rinsho. 2007;65:371–9.
Vander Lugt MT, Braun TM, Hanash S, et al. ST2 as a marker for risk of therapy-resistant
graft-versus- host disease and death. N Engl J Med. 2013;369:529–39.
Xie X, Zhang D, Chen JW, et al. Pharmacogenomics of biological treatment in rheumatoid arthritis.
Expert Opin Biol Ther. 2014;14:157–64.
17 Personalized Approaches to Immune Disorders